Tranzyme Pharma Receives FDA Fast Track Designation for its Novel Ghrelin Agonist, TZP-101, for the Treatment of Severe Gastroparesis

RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS WIRE)--Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal and metabolic diseases, today announced that the company has received fast track designation for its novel ghrelin agonist, TZP-101, for the treatment of severe gastroparesis. Tranzyme is developing TZP-101 as a first-in-class prokinetic agent for the treatment of severe gastroparesis and post-operative ileus (POI).